These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 14794457)

  • 41. Limitations of compounding diazepam suspensions from tablets.
    Newton DW; Schulman SG; Becker CH
    Am J Hosp Pharm; 1976 May; 33(5):450-2. PubMed ID: 1274959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Oral "P.A. syrup" as a premedication for fibrogastroscopy].
    Dehui D
    Zhonghua Hu Li Za Zhi; 1982 Oct; (5):303-4. PubMed ID: 6925479
    [No Abstract]   [Full Text] [Related]  

  • 43. [Preparations of suprarenal cortex hormones. II. Microcrystalline suspensions of cortisone acetate for injections].
    Nerlo H; Umer S
    Acta Pol Pharm; 1975; 32(2):217-25. PubMed ID: 1136832
    [No Abstract]   [Full Text] [Related]  

  • 44. [Late side effects on the skin after injection of cortisone crystall suspensions].
    Härtel P
    Hefte Unfallheilkd; 1969; 99():149-50. PubMed ID: 4248832
    [No Abstract]   [Full Text] [Related]  

  • 45. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
    Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
    Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
    Li Q; Liu Z; Kolli S; Wetz K; Griffith N; Poi MJ
    Am J Health Syst Pharm; 2016 Sep; 73(17):1331-7. PubMed ID: 27543577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Corticoid therapy in chronic obstructive pulmonary disease.
    Criep LH
    Geriatrics; 1973 Jan; 28(1):111-5. PubMed ID: 4683086
    [No Abstract]   [Full Text] [Related]  

  • 48. Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension.
    Bloomer D; Dupuis LL; MacGregor D; Soldin SJ
    Clin Pharm; 1987 Aug; 6(8):646-9. PubMed ID: 3691011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stability of rifabutin in two extemporaneously compounded oral liquids.
    Haslam JL; Egodage KL; Chen Y; Rajewski RA; Stella V
    Am J Health Syst Pharm; 1999 Feb; 56(4):333-6. PubMed ID: 10690216
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats.
    Kim DW; Kim YH; Yousaf AM; Kim DS; Kwon TK; Park JH; Kim YI; Park JH; Jin SG; Kim KS; Cho KH; Li DX; Kim JO; Yong CS; Woo JS; Choi HG
    Arch Pharm Res; 2016 Apr; 39(4):539-546. PubMed ID: 26983932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Paracetamol pharmacokinetics after oral administration of a single dose in the form of tablets and syrup].
    Wójcicki J; Gawrońska-Szklarz B; Baśkiewicz Z; Kałucki K
    Acta Pol Pharm; 1980; 37(3):351-4. PubMed ID: 7004090
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of crystal form, cortisone alcohol and agitation on crystal growth of cortisone acetate in aqueous suspensions.
    Carless JE; Moustafa MA; Rapson HD
    J Pharm Pharmacol; 1968 Aug; 20(8):639-45. PubMed ID: 4386552
    [No Abstract]   [Full Text] [Related]  

  • 53. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of education programs about oral antibiotic suspensions in pediatric outpatient services.
    Hu H; Wu FL; Hu FC; Yang HY; Lin SW; Shen LJ
    Pediatr Neonatol; 2013 Feb; 54(1):34-42. PubMed ID: 23445741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children.
    Pramann LA; Davidow LW; van Haandel L; Funk RS
    Int J Pharm Compd; 2016; 20(3):257-261. PubMed ID: 28333668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysing the stability of two oral carbamazepine suspensions.
    Jover Botella A; Márquez Peiró JF; González Loreiro MD; Pitaluga Poveda L; Selva Otaolaurruchi J
    Farm Hosp; 2011; 35(1):28-31. PubMed ID: 20933450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of absorption of cortisone acetate and hydrocortisone hemisuccinate.
    Fariss BL; Hane S; Shinsako J; Forsham PH
    J Clin Endocrinol Metab; 1978 Nov; 47(5):1137-40. PubMed ID: 233690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children.
    Kersten E; Barry A; Klein S
    Pharmazie; 2016 Mar; 71(3):122-7. PubMed ID: 27183705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Megestrol acetate NCD oral suspension -- Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2.
    Drugs R D; 2007; 8(4):251-4. PubMed ID: 17596111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.